

| Market Applicability/Effective Date | | | | | | | | | | | | | | |
|-------------------------------------|----------|--------|--------|----|----|----|----|----|----|----|----|----|----|----|
| Market | FL & FHK | FL MMA | FL LTC | GA | KS | KY | LA | MD | NJ | NV | NY | TN | TX | WA |
| Applicable | X | NA | NA | X | NA | X | X | X | X | X | X | NA | NA | X |

*FHK- Florida Healthy Kids

| Medication | Comments |
|----------------------|-------------------------|
| Pradaxa (dabigatran) | 60 capsules per 30 days |

VERRIDE(S)

Prior Authorization of Benefits

APPROVAL DURATION

1 Year

APPROVAL CRITERIA

Pradaxa (dabigatran) may be approved if the following criteria are met:

- I. Individual has a diagnosis of non-valvular atrial fibrillation or flutter; **AND**
- II. Individual is using to reduce the risk of stroke and systemic embolism;

OR

- III. Individual is using to treat deep vein thrombosis and pulmonary embolism; **AND**
- IV. Individual has undergone treatment with a parenteral anticoagulant for five to ten days;

OR

- V. Individual is using as prophylaxis to reduce the risk of deep vein thrombosis and/or pulmonary embolus in individuals with prior treatment;

OR

- VI. Individual is undergoing major orthopedic surgery (such as, total hip- or knee-replacement) (AHFS); **AND**
- VII. Individual is using as prophylaxis for venous thromboembolism; **AND**
- VIII. Individual cannot use low-molecular weight heparin (LMWH) [such as, diagnosis of heparin-induced thrombocytopenia (HIT)].

May not be approved for the following:

- I. Individual has a mechanical prosthetic heart valve.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

| Market Applicability/Effective Date | | | | | | | | | | | | | | |
|-------------------------------------|----------|--------|--------|----|----|----|----|----|----|----|----|----|----|----|
| Market | FL & FHK | FL MMA | FL LTC | GA | KS | KY | LA | MD | NJ | NV | NY | TN | TX | WA |
| Applicable | X | NA | NA | X | NA | X | X | X | X | X | X | NA | NA | X |

*FHK- Florida Healthy Kids

Note: Pradaxa (dabigatran) has a black box warning that the discontinuation in individuals without adequate continuous anticoagulation increases the risk of stroke. If Pradaxa must be discontinued for reasons other than pathological bleeding, coverage with another anticoagulant should be strongly considered. In addition, Pradaxa use in individual undergoing spinal epidural anesthesia or spinal puncture increases risk of epidural or spinal hematoma, possibly causing long-term or permanent paralysis. Risks and benefits should be considered before neuraxial intervention and individuals should be monitored frequently for signs of neurologic impairment and treated urgently if signs appear.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.